RBR-88jm8yk尚未招募1 期
Clinical Trial for the Assessment of Safety, Tolerance and Immune Responses toVaccine, for the Prevention of Leprosy, LepVax in Adult Participants
Instituto de Tecnologia em Imunobiológicos Bio-Manguinhos / Fiocruz0 个研究点开始时间: 2021年8月11日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Intervention
入排标准
- 年龄范围
- 18Y 至 55Y（—）
入选标准
- •Men and women between 18 years and 55 years of age;For phase 1b, they must be in good general health, confirmed by medical history and physical examination, with negative clinical assessment for leprosy. For phase 2a, the diagnosis of paucibacillary leprosy must be confirmed;Female participants of childbearing potential must test negative on a serum pregnancy test at screening and a urine pregnancy test on study vaccination days (D0, D28, and D56). They must not be breastfeeding and must use at least one method of contraception from the time of study enrollment (Day 0) until 30 days after the last injection if they have sex with men;Screening laboratory tests with normal or non-clinically significant values ??for: sodium, potassium, AST, ALT, total bilirubin, alkaline phosphatase, creatinine, glucose, total white blood cell count, hemoglobin, and platelet count. Abnormal results may be repeated at the discretion of the Responsible Researcher and/or sub-researchers, and may share doubts with the sponsor's Scientific Leader and, if necessary, with the DSMB;Negative serological tests for: Anti-HIV 1/2 antibody, hepatitis B surface antigen (HBsAg) and hepatitis C virus antibody (HCV);Normal or non-clinically significant urinalysis as determined by the study physician or designee. Abnormal results may be repeated at the discretion of the Lead Investigator;Must be able to complete the study adverse event diary; Must consent to participate in the study, be able and willing to attend all assessment visits, be accessible by telephone or home visits, and live in the region until the study follow-up is completed
排除标准
- •In phase 1b, history of Mycobacterium leprae infection.History of exposure to experimental products containing GLA-SE.History of active tuberculosis or with documented recurrence.History of previous infection with other non-tuberculous mycobacteria;Participation in another study protocol and/or administration of any study product in the last three months prior to screening.Treatment with immunosuppressive drugs (eg, oral or injectable steroids, such as prednisone; high-dose inhaled steroids) or cytotoxic therapies (eg, chemotherapy or radiotherapy) within six months of screening.Received blood transfusion in the last three months prior to screening.
- •8. Donated blood products (platelets, whole blood, plasma, etc.) in the last month before screening.Received any vaccine one month prior to screening or planned immunizations during follow-up from D0 to D63 and D154 to D168.History of autoimmune disease or other immunosuppressive causes.History of any other decompensated acute or chronic illness (including cardiovascular, pulmonary, neurological, hepatic, rheumatic, hematological, metabolic or renal disease, uncontrolled hypertension) or use of medications that, in the opinion of the Responsible Investigator, may interfere with safety or immunogenicity of the vaccine.Skin rash, tattoos, or any other dermatological condition that may adversely affect the vaccine injection site or interfere with its evaluation.Body mass index (BMI) = 32.Systemic arterial hypertension (systolic > 150 or diastolic > 95).History of psychiatric illness with current medication use.
- •16. Alcohol or drug abuse in the last six months prior to screening.Chronic smoker (one pack or more per day).History of previous anaphylaxis or severe allergic reaction to vaccines or unknown allergens.Individuals who do not wish to cooperate with all procedures recommended in the study protocol.
研究者
相似试验
已完成
不适用
A clinical trial to evaluate the safety, tolerability, and pharmacokinetics of single and multiple ascending oral doses of LEO 153339 in healthy subjectsPsoriasisNL-OMON51974eo Pharma A/S134
进行中（未招募）
不适用
Study in healthy subjects and type 2 diabetic subjects to assess the safety, tolerability and pharmacokinetics of 28 days EV-077-3201-2TBS treatment, and the effects of thromboxane receptor antagonism on platelet function, vascular inflammation and vascular oxidative stressHealthy subjects and subjects with Type 2 DiabetesMedDRA version: 14.1Level: LLTClassification code 10045242Term: Type II diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2011-003808-20-DEEvolva SA96
已完成
Unknown
A study to evaluate the Safety, In-Use Tolerability and Efficacy of a test product in reducing acne and acne spots on the face.CTRI/2023/10/058218Himalaya Wellness Company102
已完成
Unknown
A study to evaluate the Safety and Efficacy of 1 test product in reducing dark spots on the face.CTRI/2023/03/050575Himalaya Wellness Company42
终止
1 期
A phase 1 Trial Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics and the Food Effect on the Safety and Pharmacokinetics of OPC-131066healthy adultJPRN-jRCT2080224712Otsuka Pharmaceutical Co., LTD.122